Dr. Nathan Pennell joined the Taussig Cancer Center at the Cleveland Clinic, where he currently serves as the director of the TCI Lung Cancer Medical Oncology Program. A specialist in treating thoracic malignancies, Dr. Pennell is especially interested in lung cancer, mesothelioma, thyroid cancer and symptoms related to chemotherapy. He is active in clinical trials aimed at testing innovative therapies and bringing them to the public more quickly.
Of multimodal treatment, Dr. Pennell writes: “It would appear that it is possible for some patients, specifically those with no mediastinal nodal involvement, to be cured of malignant mesothelioma with aggressive trimodality therapy…. I do think there is a role for surgery in mesothelioma and any advancement that leads to cures in this terrible disease is fantastic, but until this can be applied to a larger percentage of the patients I think it will remain out of reach for most patients.”
His numerous publications focus on multimodal approaches to untreatable lung cancers and on the use of genetic markers. His work frequently appears in The Journal of Thoracic Oncology. He is also a faculty member of GRACE, the Global Resource for Advancing Cancer Education, a nonprofit dedicated to providing information about cutting-edge cancer research directly to patients. For GRACE, he has written about trimodality therapy for mesothelioma, as well as the role of molecular markers in lung cancer.
Main Specialty: Oncology
Other Interests & Specialties: General oncology, hematologic oncology, thoracic cancer, chemotherapy-related symptoms, lung cancer, mesothelioma, thymic cancer, thymic tumors and thyroid cancer.
Certifications, Awards & Accolades: Associate Editor of ASCO Educational Book, Best Doctors in America Award, Best Doctors Award, Teacher of the Year Award, Foundation Merit Award
Education & Experience:
- Residency at Brigham and Women’s Hospital
- Fellowship in Medical Oncology at Dana-Farber Cancer Institute
- Medical Degree from University of Florida College of Medicine
Prospective Clinical Study of Precision Oncology in Solid Tumors. Journal of the National Cancer Institute. March 2016; 108(3): 332-335. doi: 10.1093/jnci/djv332
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. September 2018; 13(9): 1393-1399. doi: 10.1016/j.jtho.2018.05.002
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology. November 2018; 13(11): 1655-1667. doi: 10.1016/S1556-0864(18)33138-1
- Mesothelioma Doctors
- Cancer Centers
- Treatment Near You
- Experimental Treatments
- Alternative Treatments
- Clinical Trials
- Caregiver Resources
- Treatment Costs